Delivery Order SPE2DB24D2208-SPE2DB25FHHTD
- Not listed
- The Defense Logistics Agency awarded a $6,030.23 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Multaq 400 mg tablets (60-count units). This firm fixed-price contract, which is a child order under a larger vehicle, represents a competitive award with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order draws...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,549.80 on July 29, 2025, for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 30, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,392.45 for 60 tablets of Multaq 400 mg on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed price, competitively awarded contract (no set-aside used) is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) valued at $3,359.77, with an ultimate completion date of September 11, 2025. This competitive award, issued September 10, 2025, utilizes firm fixed-price pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a $1,866.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Multaq 400 mg tablets (60-count units). The contract, with an ultimate completion date of July 24, 2025, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. This award involved no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Multaq 400 mg tablets (60-count) with a ceiling value of $38,737.23. This firm fixed-price delivery order, with an ultimate completion date of September 22, 2025, represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The...
- The Defense Logistics Agency awarded a $10,499.79 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Multaq 400 mg tablets (60-count units). This competitive award, with no set-aside designation, represents a firm fixed-price delivery order with an ultimate completion date of September 5, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $1,446.40. This competitively awarded, firm fixed-price delivery order was issued on June 2, 2025, with an ultimate completion date of June 3, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is located. This award carries no set-aside designation, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $24,960.51 with firm fixed pricing. This competitively awarded, non-set-aside contract is scheduled for completion by September 15, 2025, with performance of work occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Multaq 400 mg tablets (60-count packages) with a ceiling value of $7,665.52. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award under the company's broader pharmaceutical supply agreement with DLA. The contract specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania location with an ultimate...
- SPE2DB24D2208Indefinite Delivery Contract
- SPE2DB24D2208-SPE2DB25FHHTDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $16,683.12 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on June 4, 2025, with completion scheduled for June 5, 2025. This competitive award, issued without set-aside designation, utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The Multaq supply fulfills ongoing pharmaceutical support requirements across the Defense Health Agency and other federal healthcare programs, consistent with the company's extensive portfolio of brand-name and generic drug deliveries across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.7k | 6/4/25 |